Čes. slov. farm. 2023, 72(1):37-44 | DOI: 10.5817/CSF2023-1-37

New trends in advanced parkinson disease stage therapy

Mária Kolesárová¹, Ondrej Franko¹, Dalibor Kolesár², Andrea Gažová^3,*, Ján Kyselovič^1,4

¹ Katedra farmakológie a toxikológie, Univerzita veterinárskeho lekárstva a farmácie Košice, Slovenská republika

² Ústav anatómie LF UPJŠ Košice, Slovenská republika

³ Ústav farmakológie a klinickej farmakológie LF UK, Bratislava, Slovenská republika

⁴ V. interná klinika LF UK a Univerzitná nemocnica Bratislava, Nemocnica Ružinov Bratislava, Slovenská republika

The aim of the study was to point out the contribution of new invasive therapeutic procedures in the treatment of advanced stages of Parkinson's disease (PD) in comparison with classical oral pharmacotherapy. Data originated from a group of 43 patients with PD, 39% (17) with classic treatment, 23% (10) with intestinal gel of methyl ester levodopa (Duodopa), 19% (8) of patients were using subcutaneous delivery of apomorphine (APO) and the same quantity of patients had undergone deep brain stimulation (DBS). Majority of patients had advanced stages of PD, stage 4, by standards of Hoehn and Yahr scale (Hoehn and Yahr, 1967). Research observed improvement in majority of patients with novel treatments. A positive effect was also noted in the reduced need for oral therapy, where there was a significant decrease in all new therapies. Benefits were observed in the amount of antiparkinsonic drugs taken per os, where we observed reduction in all new therapies. A positive effect of the new therapeutic approaches in reducing "off" periods in patients has also been noted. In the case of Duodopa and DBS, the "off" period was shortened up to 50% and in the apomorphine pump up to 40%. Patients also reported reduction of some symptoms like rigidity, tremor and bradykinesis while dyskinesis still remains suba challenge. On the basis of the obtained results, it can be concluded that new therapeutic procedures for PCh will make it possible to manage symptoms typical of advanced stages of the disease, which without these procedures would lead to disability, which is the main reason for their indication. However, in early stages, well responding patients or in slow progressing disease oral antiparkinsonics are remaining as golden standard of treatment. This is not just due to good response but also because these classic drug formulations are significantly less expensive. In Slovakia, novel treatments are accessible through healthcare insurance only after secondary revision by insurance company doctors.

Keywords: Parkinson's disease; deep brain stimulation; pharmacotherapy; Duodopa; apomorphine pump

Received: September 7, 2022; Accepted: December 2, 2022; Published: January 1, 2023  Show citation